Drug Trial Radar · NCT07842393
A Study of IBI3042 in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Oct 20, 2026
Primary completion
Mar 2, 2027
Study completion Mar 2, 2027
Sponsor
- Lead sponsor
- Fortvita Biologics (USA)Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, investigator- and participant-blinded, placebo-controlled, parallel-group, dose-escalation Phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of single ascending oral doses of IBI3042, in healthy adult participants. Approximately 32 healthy participants will be enrolled across 4 single ascending dose groups, with 8 participants per group randomized in a 6:2 ratio to receive a single oral dose of IBI3042 or matching placebo. A sentinel-dosing design is used for the first dose cohort. Safety and PK data are assessed to support dose escalation decisions by the Safety Review Committee.
Conditions
- Healthy Volunteers (HV)
Interventions
Investigational Drug: IBI3042Drug
Oral, corresponding dose regimen according to study cohort
Matching PlaceboDrug
Oral, matching to IBI3042, corresponding dose regimen according to study cohort
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: through study completion, an average of 29 days
- Number of Participants With Clinically Significant Abnormal Vital SignsTime frame: through study completion, an average of 29 days
- Number of Participants With Clinically Significant Abnormal 12-lead electrocardiogramTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal General Appearance FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Respiratory FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Cardiovascular FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Abdominal FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Skin FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Head and Neck FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Lymph Node FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Thyroid FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Musculoskeletal FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Neurological FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Blood Routine FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Blood Biochemistry FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Coagulation FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Urine Routine FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Calcitonin FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Glycated Hemoglobin FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Infection-Related Immunology FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Thyroid Function FindingsTime frame: through study completion, an average of 29 days
- Number of Participants With Abnormal Pregnancy Test FindingsTime frame: through study completion, an average of 29 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Lenexa
Lenexa, Kansas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.